Thomasville National Bank Increases Stake in Zoetis Inc. (NYSE:ZTS)

Thomasville National Bank boosted its position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 6.4% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 84,289 shares of the company's stock after buying an additional 5,075 shares during the period. Thomasville National Bank's holdings in Zoetis were worth $13,878,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of ZTS. Callahan Advisors LLC boosted its stake in Zoetis by 90.4% in the fourth quarter. Callahan Advisors LLC now owns 13,105 shares of the company's stock valued at $2,135,000 after buying an additional 6,221 shares in the last quarter. CIBC Asset Management Inc boosted its stake in shares of Zoetis by 24.1% in the 4th quarter. CIBC Asset Management Inc now owns 237,369 shares of the company's stock valued at $38,617,000 after purchasing an additional 46,050 shares in the last quarter. Schroder Investment Management Group boosted its stake in shares of Zoetis by 2.6% in the 4th quarter. Schroder Investment Management Group now owns 245,726 shares of the company's stock valued at $40,036,000 after purchasing an additional 6,169 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Zoetis by 0.3% during the 4th quarter. Vanguard Group Inc. now owns 41,366,877 shares of the company's stock valued at $6,739,905,000 after purchasing an additional 120,158 shares during the last quarter. Finally, Portside Wealth Group LLC increased its position in Zoetis by 24.7% during the 1st quarter. Portside Wealth Group LLC now owns 33,709 shares of the company's stock worth $5,550,000 after purchasing an additional 6,672 shares in the last quarter. 92.80% of the stock is owned by institutional investors.

Zoetis Price Performance

Shares of ZTS traded down $4.55 during trading hours on Friday, reaching $164.27. 2,973,481 shares of the company's stock traded hands, compared to its average volume of 2,551,303. Zoetis Inc. has a 12 month low of $139.70 and a 12 month high of $200.33. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09. The stock has a market cap of $73.13 billion, a PE ratio of 30.03, a price-to-earnings-growth ratio of 2.78 and a beta of 0.94. The firm's 50 day simple moving average is $158.26 and its 200-day simple moving average is $164.09.

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported $1.48 earnings per share for the quarter, beating analysts' consensus estimates of $1.40 by $0.08. The company had revenue of $2.22 billion for the quarter, compared to analysts' expectations of $2.20 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. Zoetis's revenue for the quarter was up 1.4% compared to the same quarter last year. During the same period last year, the firm posted $1.38 EPS. Equities analysts expect that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 3rd. Stockholders of record on Friday, July 18th will be given a $0.50 dividend. The ex-dividend date is Friday, July 18th. This represents a $2.00 annualized dividend and a dividend yield of 1.22%. Zoetis's dividend payout ratio is 35.91%.

Insider Activity

In related news, EVP Roxanne Lagano sold 652 shares of the company's stock in a transaction on Tuesday, June 3rd. The stock was sold at an average price of $170.00, for a total value of $110,840.00. Following the sale, the executive vice president now directly owns 15,129 shares of the company's stock, valued at $2,571,930. This represents a 4.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 0.18% of the company's stock.

Analyst Ratings Changes

ZTS has been the topic of a number of research reports. Piper Sandler boosted their target price on shares of Zoetis from $205.00 to $210.00 and gave the stock an "overweight" rating in a report on Monday, May 12th. Wall Street Zen raised shares of Zoetis from a "hold" rating to a "buy" rating in a research note on Friday, March 7th. UBS Group cut their target price on Zoetis from $189.00 to $170.00 and set a "neutral" rating on the stock in a report on Wednesday, May 7th. Stifel Nicolaus decreased their price target on Zoetis from $180.00 to $165.00 and set a "buy" rating for the company in a research note on Monday, April 14th. Finally, Morgan Stanley lowered their price objective on Zoetis from $243.00 to $238.00 and set an "overweight" rating for the company in a research report on Friday, February 14th. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat, Zoetis presently has a consensus rating of "Buy" and a consensus target price of $212.75.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.